Cogent Biosciences, Inc. financial data

Symbol
COGT on Nasdaq
Location
Waltham, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 17 Feb 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 772% % -1.3%
Debt-to-equity 46% % 152%
Return On Equity -100% % -34%
Return On Assets -68% % -8.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 162,308,820 shares
Common Stock, Shares, Outstanding 160,980,024 shares 46%
Entity Public Float $772,900,000 USD -11%
Common Stock, Value, Issued $161,000 USD 46%
Weighted Average Number of Shares Outstanding, Basic 128,899,408 shares 24%
Weighted Average Number of Shares Outstanding, Diluted 128,899,408 shares 24%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $269,780,000 USD 16%
General and Administrative Expense $63,583,000 USD 47%
Costs and Expenses $333,363,000 USD 21%
Operating Income (Loss) $333,363,000 USD -21%
Nonoperating Income (Expense) $4,426,000 USD -78%
Net Income (Loss) Attributable to Parent $328,937,000 USD -29%
Earnings Per Share, Basic -2.16 USD/shares -11%
Earnings Per Share, Diluted -2.16 USD/shares -11%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $312,012,000 USD 218%
Assets, Current $910,355,000 USD 207%
Property, Plant and Equipment, Net $5,457,000 USD -16%
Operating Lease, Right-of-Use Asset $18,078,000 USD -10%
Other Assets, Noncurrent $3,301,000 USD -32%
Assets $937,607,000 USD 186%
Accounts Payable, Current $9,504,000 USD -21%
Employee-related Liabilities, Current $15,740,000 USD 28%
Liabilities, Current $63,953,000 USD 15%
Operating Lease, Liability, Noncurrent $14,355,000 USD -9.7%
Other Liabilities, Noncurrent $33,000 USD
Liabilities $301,236,000 USD 321%
Accumulated Other Comprehensive Income (Loss), Net of Tax $355,000 USD -21%
Retained Earnings (Accumulated Deficit) $1,188,420,000 USD -38%
Stockholders' Equity Attributable to Parent $636,371,000 USD 148%
Liabilities and Equity $937,607,000 USD 186%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $66,511,000 USD -27%
Net Cash Provided by (Used in) Financing Activities $24,970,000 USD -88%
Net Cash Provided by (Used in) Investing Activities $69,379,000 USD 6545%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 160,980,024 shares 46%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $27,838,000 USD -83%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $312,428,000 USD 218%
Deferred Tax Assets, Valuation Allowance $311,030,000 USD 42%
Operating Lease, Liability $15,902,000 USD -9%
Payments to Acquire Property, Plant, and Equipment $547,000 USD 681%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $329,029,000 USD -29%
Lessee, Operating Lease, Liability, to be Paid $30,116,000 USD 19%
Property, Plant and Equipment, Gross $14,136,000 USD 12%
Operating Lease, Liability, Current $1,547,000 USD -1.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two $3,148,000 USD 17%
Lessee, Operating Lease, Liability, to be Paid, Year One $2,950,000 USD 3.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $14,214,000 USD 83%
Lessee, Operating Lease, Liability, to be Paid, Year Three $3,227,000 USD 51%
Deferred Tax Assets, Operating Loss Carryforwards $100,592,000 USD 56%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $3,307,000 USD 52%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $46,079,000 USD 16%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%